Summary
It has been suggested in a number of studies that susceptibility to adult Hodgkin’s disease (HD) is influenced by the HLA class II region, and specifically by alleles at the HLA-DPB1 locus. Since HD is diagnostically complex, it is not clear whether different HLA-DPB1 alleles confer susceptibility to different HD subtypes. To clarify this we have extended a previous study to type DPB1 alleles in 147 adult HD patients from a single centre. We have analysed patients with nodular sclerosing (NS), mixed cellularity (MC) or lymphocyte predominant (LP) HD, and gender in relation to HLA-DPBI type, in comparison with 183 adult controls. The results confirmed previously reported associations of DPB1*0301 with HD susceptibility (relative risk (RR) = 1.42; 95% confidence interval (CI) 0.86–2.36) and DPB1*0201 with resistance to HD (RR = 0.49; CI 0.27–0.90). However, analysis by HD subtype and gender showed that *0301-associated susceptibility was confined to females with HD (RR = 2.46; CI 1.02–5.92), and *0201-associated resistance to females with NS-HD (RR = 0.28; CI 0.10–0.79). Susceptibility to NS-HD was also associated in females with *1001 (RR = 11.73; CI 1.32–104.36), and resistance with *1101 (RR = 0.08; CI 0.01–0.65). In contrast, susceptibility to LP-HD was associated in males with *2001 (RR = 32.14; CI 3.17–326.17), and to MC-HD with *3401 (RR = 16.78; CI 2.84–99.17). Comparison of DPB1-encoded polymorphic amino-acid frequencies in patients and controls showed that susceptibility to MC-HD was associated with Leucine at position 35 of DPB1 (RR = 8.85; CI 3.04–25.77), Alanine-55 (RR = 15.17; CI 2.00–115.20) and Valine-84 (RR = 15.94; CI 3.55–71.49). In contrast, Glutamic acid 69 was significantly associated with resistance to MC-HD (RR = 0.14; CI 0.03–0.60). Certain DPB1 alleles and individual DPβ1 polymorphic amino acid residues may thus affect susceptibility and resistance to specific HD subtypes. This may be through their influence on the binding of peptides derived from an HD-associated infectious agent, and the consequent effect on immune responses to the agent.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alexander, F. E., Ricketts, T. J., McKinney, P. A. & Cartwright, R. A. (1991a). Community lifestyle characteristics and incidence of Hodgkin’s disease in young people. Int J Cancer 48: 10–14.
Alexander, F. E., McKinney, P. A., Williams, J., Ricketts, T. J. & Cartwright, R. A. (1991b). Epidemiological evidence for the ‘two-disease hypothesis’ in Hodgkin’s disease. Int J Epidemiol 20: 354–361.
Bodmer, J. G., Tonks, S., Oza, A. M., Lister, T. A. & Bodmer, W. F. (1989). HLA-DP-based resistance to Hodgkin’s disease. Lancet i: 1455–1456.
Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L. & Wiley, D. C. (1993). Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33–39.
Bugawan, T. L., Begovich, A. B. & Erlich, H. A. (1990). Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes. Immunogenetics 32: 231–241.
Cesbron, A., Moreau, P., Rapp, M. J., Cheneau, M. L., Herry, P., Bonneville, F., Muller, J. Y., Harrouseau, J. L. & Bignon, J. D. (1993). HLA-DPB and susceptibility to Hodgkin’s disease. Hum Immunol 36: 51
Fu, X-T, Bono, C. P., Woulfe, S. L., Swearingen, C., Summers, N. L., Sinigaglia, F., Sette, A., Schwartz, B. D. & Karr, R. W. (1995). Pocket 4 of the HLA-DR (α,β*0401) molecule is a major determinant of T cell recognition of peptide. J Exp Med 181: 915–926.
Germain, R. N. (1994). MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76: 287–299.
Glaser, S. L. & Jarrett, R. F. (1996). The epidemiology of Hodgkin’s disease. Ballière’s Clin Haematol 9: 401–416.
Gokhale, D. A., Evans, D. G., Crowther, D., Woll, P., Watson, C. J., Dearden, S. P., Fergusson, W. D., Stevens, R. F. & Taylor, G. M. (1995). Molecular genetic analysis of a family with a history of Hodgkin’s disease and dyschondrosteosis. Leukemia 9: 826–833.
Gutensohn, N. & Cole, P. (1977). Epidemiology of Hodgkin’s disease in the young. Int J Cancer 19: 595–604.
Gutensohn, N. & Cole, P. (1981). Childhood social environment and Hodgkin’s disease. N Engl J Med 304: 135–140.
Hammer, J. (1995). New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol 7: 263–269.
Hammer, J., Gallazzi, F., Bono, E., Karr, R. W., Guenot, J., Valsasnini, P., Nagy, Z. A. & Sinigaglia, F. (1995). Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 181: 1847–1855.
Jarrett, R. F. (1993). Viruses and Hodgkin’s disease. Leukemia 7: S78–S82.
Khan, G., Coates, P. J., Gupta, R. K., Kangro, H. O. & Slavin, G. (1992). Presence of Epstein-Barr virus in Hodgkin’s disease is not exclusive to Reed–Sternberg cells. Am J Pathol 140: 757–762.
Klitz, W., Aldrich, C. L., Fildes, N., Horning, S. J. & Begovich, A. B. (1994). Localization of predisposition to Hodgkin’s disease in the HLA class II region. Am J Hum Genet 54: 497–505.
Lukes, R. J., Butler, J. J. & Hicks, E. B. (1966a). Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 19: 317–344.
Lukes, R. J., Craver, L. F., Hall, T. C., Rappaport, H. & Ruben, P. (1966b). Report of the nomenclature committee. Cancer Res 26: 1311
Marsh, S. G. (1996). Nomenclature for factors of the HLA system, update May/June 1997: WHO Nomenclature Committee for Factors of the HLA system. Tissue Antigens 50: 419–420.
Mantel, N. & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
Mauch, P. M., Kalish, L. A., Kadin, M., Coleman, C. N., Osteen, R. & Hellman, S. (1993). Patterns of presentation of Hodgkin disease. Cancer 71: 2062–2071.
Miller, G. (1990). Epstein–Barr virus: biology, pathogenesis and medical aspects. In Field’s Virology, Fields BN, Snipe DM, Chanock RM et al Raven Press: New York 1921–1958.
Nei, M. & Roychoudhury, A. K. (1974). Sampling variances of heterozygosity and genetic distance. Genetics 76: 379–390.
Oudejans, J. J., Jiwa, N. M. & Meijer, CJLM (1997). Epstein-Barr virus in Hodgkin’s disease: more than just an innocent bystander. J Pathol 181: 353–356.
Oza, A. M., Tonks, S., Lim, J., Fleetwood, M. A., Lister, T. A. & Bodmer, J. G. Collaborating Centers (1994). A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkins disease. Cancer Res 54: 5101–5105.
Pan, L. X., Diss, T. C., Peng, H. Z., Norton, A. J. & Isaacson, P. G. (1996). Nodular lymphocyte predominance Hodgkin’s disease: a monoclonal or polyclonal B-cell disorder?. Blood 87: 2428–2434.
Pellegris, G., Lombardo, C., Cantoni, A., Devizzi, L. & Balzarotti, M. (1993). Study of the HLA-DPβ1 locus by the polymerase chain reaction technique in patients with Hodgkin’s disease. Tumori 79: 133–136.
Potolicchio, I., Mosconi, G., Forni, A., Nemery, B., Seghizzi, P. & Sorrentino, R. (1997). Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol 27: 2741–2743.
Radford, J. A., Crowther, D., Rohatiner, A. Z. S., Ryder, W. D. J., Gupta, R. K., Oza, A., Deakin, D. P., Arnott, S., Wilkinson, P. M., James, R. D., Johnston, R. J. & Lister, T. A. (1995). Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, Ch1VPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol 13: 2379–2385.
Sheehe, P. R. (1966). Combination of log relative risk in retrospective studies of disease. Am J Pub Health Nations Health 56: 1745–1750.
Skare, J. C., Grierson, H. L., Sullivan, J. L., Nussbaum, R. L., Putilo, D. T., Sylla, B. S., Lenoir, G. M., Reilly, D. S., White, B. N. & Milunsky, A. (1989). Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Human Genet 82: 354–358.
Sokal, R. R. & Rohlf, F. J. (1995). Biometry, 3rd edn WH Freeman: New York
Tait, B. D., Bodmer, J. G., Erlich, H. A., Ferrara, G. B., Albert, E., Begovich, A., Kimura, A., Varney, M. D. & Klitz, W. (1991). DNA typing: DPA and DPB analysis. In HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference 1: Tsuji K, Aizawa M, Sasazuki T Oxford Science: Oxford 485–496.
Taylor, G. M., Gokhale, D. A., Crowther, D., Woll, P., Harris, M., Alexander, F., Jarrett, R. & Cartwright, R. A. (1996). Increased frequency of HLA-DPB1*0301 in Hodgkin’s disease suggests that susceptibility is HVR-sequence and subtype associated. Leukemia 10: 854–859.
Tonks, S., Oza, A. M., Lister, T. A. & Bodmer, J. G. Collaborating Centres (1991). An international study of the association between HLA-DP and Hodgkin’s disease. In HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference 2: Tsuji K, Aizawa M, Sasazuki M Oxford Science: Oxford 539–544.
Tonks, S., Oza, A. M., Lister, T. A. & Bodmer, J. G. (1992). Association of HLA-DPB with Hodgkin’s disease. Lancet i 340: 968–969.
Vianna, N. J., Greenwald, P. & Davies, J. N. P. (1971). Nature of Hodgkin’s disease agent. Lancet i: 733–736.
Vianna, N. J. (1974). Is Hodgkin’s disease infectious? Cancer Res 34: 1149–1155.
Weiss, L. M., Movahed, L. A., Warnke, R. A. & Sklar, J. (1989). Detection of Epstein–Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med 320: 502–506.
Wu, T-C, Mann, R. B., Charache, P., Hayward, S. D., Staal, S., Lambe, B. C. & Ambinder, R. F. (1990). Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin’s disease. Int J Cancer 46: 801–804.
Zerva, L., Cizman, B., Mehra, N. K., Alahari, S. K., Murali, R., Zmijewski, C. M., Kamoun, M. & Monos, D. S. (1996). Arginine at positions 13 or 70–71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibilty to tuberculoid leprosy. J Exp Med 183: 829–836.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Taylor, G., Gokhale, D., Crowther, D. et al. Further investigation of the role of HLA-DPB1 in adult Hodgkin’s disease (HD) suggests an influence on susceptibility to different HD subtypes. Br J Cancer 80, 1405–1411 (1999). https://doi.org/10.1038/sj.bjc.6690536
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690536
Keywords
This article is cited by
-
Genetic susceptibility to chronic lymphocytic leukemia
Leukemia (2002)